RPL23A Antibody

What is RPL23A and what cellular functions does it perform?

RPL23A (Ribosomal Protein L23a) is a component of the 60S subunit of the ribosome, the cellular machinery responsible for protein synthesis. It functions as a critical structural component of the large ribosomal subunit and plays an essential role in the translation process . RPL23A binds to specific regions of 26S rRNA, helping maintain ribosomal integrity and functionality during protein synthesis . Beyond its structural role, research indicates that RPL23A may have additional functions, including potential involvement in p53/TP53 regulation by promoting its degradation through the stimulation of MDM2-mediated TP53 polyubiquitination . This suggests RPL23A may participate in cellular stress response pathways beyond its canonical ribosomal function. The protein has a calculated molecular weight of 18 kDa, though it may be observed between 18-23 kDa in experimental conditions due to post-translational modifications .

What applications are RPL23A antibodies suitable for in research settings?

RPL23A antibodies are versatile research tools validated for multiple experimental applications critical to investigating ribosomal biology and protein expression. Western blotting (WB) is perhaps the most widely utilized application, with RPL23A antibodies demonstrating high sensitivity at dilutions ranging from 1:500 to 1:12000 depending on the specific antibody formulation and sample type . Immunoprecipitation (IP) is another validated application, typically using 0.5-4.0 μg of antibody for 1.0-3.0 mg of total protein lysate . Immunohistochemistry (IHC) applications generally employ dilutions between 1:50 and 1:2400, allowing visualization of RPL23A in fixed tissue sections . Additionally, RPL23A antibodies have been validated for immunofluorescence/immunocytochemistry (IF/ICC) applications at dilutions ranging from 1:20 to 1:200, enabling subcellular localization studies . RNA immunoprecipitation (RIP) represents an advanced application mentioned in published literature, allowing investigation of RNA-RPL23A interactions .

What sample types have been validated for RPL23A antibody detection?

RPL23A antibodies have been extensively validated across multiple species and sample types, providing researchers flexibility in experimental design. Human samples showing positive reactivity include cell lines such as HeLa, HepG2, 293T, and Jurkat, as well as tissue samples including liver, heart, colon, brain, and testis . Mouse samples with confirmed reactivity include liver tissue, brain tissue, and NIH/3T3 cells . Rat samples have also been validated, including liver tissue and brain tissue lysates . This cross-species reactivity is supported by the high conservation of RPL23A protein sequence across mammalian species. The extensive validation across multiple sample types provides researchers confidence in antibody performance across diverse experimental systems. Most commercially available RPL23A antibodies are rabbit polyclonal formulations that recognize specific epitopes within the human RPL23A protein, with documented cross-reactivity to mouse and rat orthologs .

What are the recommended storage conditions and handling procedures for RPL23A antibodies?

Proper storage and handling of RPL23A antibodies are essential for maintaining their performance and extending shelf life. The recommended storage temperature for RPL23A antibodies is -20°C, where they typically remain stable for one year after shipment . Most commercially available RPL23A antibodies are supplied in a storage buffer containing PBS with 0.02% sodium azide and 50% glycerol at pH 7.3, which helps maintain antibody stability during freeze-thaw cycles . For the 20μL size formulations, 0.1% BSA may be included as a stabilizing protein . Importantly, aliquoting is generally unnecessary for -20°C storage due to the glycerol content of the storage buffer, which prevents freeze-thaw damage . When handling the antibody, researchers should avoid repeated freeze-thaw cycles, maintain sterile conditions, and follow proper laboratory safety protocols, particularly due to the presence of sodium azide in the storage buffer, which can form explosive compounds in metal plumbing systems if disposed improperly.

How can researchers optimize Western blot protocols for detecting RPL23A in different experimental contexts?

Optimizing Western blot protocols for RPL23A detection requires careful consideration of several technical parameters based on experimental context. The recommended primary antibody dilution ranges significantly between products (1:500-1:12000), necessitating empirical determination for each research setting . For cell line lysates such as HeLa or HepG2, starting with mid-range dilutions (1:2000-1:5000) often provides acceptable signal-to-noise ratios . When working with tissue samples, particularly those with lower RPL23A expression, more concentrated antibody applications (1:500-1:2000) may be necessary . Sample preparation critically impacts detection sensitivity – when using whole cell lysates, loading 15-50 μg of total protein typically yields detectable RPL23A bands, as demonstrated in validated protocols using HeLa, 293T, and Jurkat cell lysates . The expected molecular weight for RPL23A is approximately 18 kDa, though variations between 18-23 kDa have been observed, potentially reflecting post-translational modifications or species-specific differences . For optimal results, researchers should employ PVDF membranes, include appropriate positive controls (such as HeLa cell lysate), and consider extended blocking steps (5% non-fat milk in TBST for 1-2 hours) to minimize background when detecting this abundant ribosomal protein.

What approaches can address cross-reactivity or specificity concerns when using RPL23A antibodies?

Addressing specificity concerns with RPL23A antibodies requires implementing rigorous validation strategies due to the high conservation of ribosomal proteins across species and potential cross-reactivity with related ribosomal proteins. The most definitive approach involves utilizing knockout/knockdown controls, which several publications have successfully employed for RPL23 antibody validation . Researchers should consider peptide competition assays, where pre-incubation of the antibody with the immunizing peptide should abolish specific signals while leaving non-specific signals intact . When comparing results across different antibody clones, researchers should pay careful attention to the immunogen information – some RPL23A antibodies target epitopes within the N-terminal region (amino acids 1-100), while others target C-terminal regions (amino acids 100 to C-terminus) . To minimize cross-reactivity with the related RPL23 protein (also a 60S ribosomal component with similar molecular weight), careful antibody selection based on immunogen uniqueness is critical . Additionally, employing comprehensive blocking strategies (5-10% normal serum from the same species as the secondary antibody) and including multiple negative controls (secondary antibody alone, isotype controls) can help distinguish specific from non-specific signals.

How can researchers effectively use RPL23A antibodies to investigate its role in p53/TP53 regulation?

Investigating RPL23A's role in p53/TP53 regulation requires specialized experimental approaches beyond standard protein detection methods. Co-immunoprecipitation (Co-IP) assays can be employed to study direct interactions between RPL23A and components of the p53 regulatory pathway, particularly MDM2 . For these experiments, researchers should optimize IP conditions using 0.5-4.0 μg of RPL23A antibody per 1.0-3.0 mg of total protein lysate from cells expressing both RPL23A and components of the p53 pathway . Proximity ligation assays (PLA) offer an alternative approach to visualize and quantify interactions between RPL23A and p53/MDM2 with subcellular resolution, though this application would require additional validation. For functional studies, combined knockdown/overexpression approaches where RPL23A levels are modulated (using siRNA or expression vectors) followed by assessment of p53 stability and ubiquitination state can provide mechanistic insights . Polyubiquitination assays using immunoprecipitation of p53 followed by ubiquitin detection in the presence of altered RPL23A levels can directly test the hypothesis that RPL23A promotes MDM2-mediated p53 polyubiquitination . These approaches should be complemented with careful controls accounting for potential indirect effects through ribosome dysfunction when manipulating RPL23A levels.

What are the technical considerations for using RPL23A antibodies in immunohistochemistry of different tissue types?

Immunohistochemical detection of RPL23A requires specific technical considerations due to its ubiquitous expression in ribosomes across various tissue types. Antigen retrieval methods significantly impact staining quality – for RPL23A, Tris-EDTA buffer at pH 9.0 is primarily recommended, though citrate buffer at pH 6.0 provides an acceptable alternative in some contexts . Optimal primary antibody dilutions vary by tissue type: for human colon samples, dilutions between 1:600-1:2400 have been validated, while human brain tissue may require more concentrated applications (1:50-1:500) . The cellular localization pattern of RPL23A staining should primarily show cytoplasmic distribution with nucleolar enrichment, reflecting its ribosomal function . When evaluating staining results, researchers should implement rigorous controls including negative controls (primary antibody omission, isotype controls) and positive controls (tissues with known high RPL23A expression such as rapidly proliferating epithelial cells) . For multiplexed studies examining RPL23A alongside other markers, sequential rather than simultaneous antibody application is recommended to minimize cross-reactivity issues, with RPL23A detection optimally performed first due to its abundance . Careful optimization of blocking steps (3-5% normal serum, 30-60 minutes) is essential to reduce background staining, particularly in tissues with high endogenous peroxidase activity or biotin content.

What methodological approaches can be employed to study RPL23A's interactions with 26S rRNA?

Studying RPL23A's interactions with 26S rRNA requires specialized techniques beyond standard protein analysis methods. RNA immunoprecipitation (RIP) has been successfully employed in published research, allowing isolation and identification of RNA species bound to RPL23A in vivo . For RIP experiments, researchers should use appropriately validated RPL23A antibodies at concentrations suitable for immunoprecipitation (0.5-4.0 μg per reaction) . Cross-linking immunoprecipitation (CLIP) and its variants (PAR-CLIP, iCLIP) offer enhanced resolution for mapping precise RPL23A binding sites on 26S rRNA, though these applications would require additional validation with available antibodies. In vitro binding assays using recombinant RPL23A protein and synthesized rRNA fragments can complement in vivo approaches, allowing detailed mapping of binding domains and assessment of binding kinetics. Structural studies leveraging cryo-electron microscopy of ribosomes can provide high-resolution insights into RPL23A-rRNA interactions within the native ribosomal context. When designing these experiments, researchers should consider that RPL23A binds specific regions on the 26S rRNA as reported in structural studies, and experimental designs should account for the complex tertiary structure of rRNA that may influence binding site accessibility .